Botulinum toxin type A + Placebo

ApprovedCompleted
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Muscle Spasticity

Conditions

Muscle Spasticity, Cerebrovascular Accident

Trial Timeline

Feb 1, 2003 → Oct 1, 2007

About Botulinum toxin type A + Placebo

Botulinum toxin type A + Placebo is a approved stage product being developed by Ipsen for Muscle Spasticity. The current trial status is completed. This product is registered under clinical trial identifier NCT00234546. Target conditions include Muscle Spasticity, Cerebrovascular Accident.

What happened to similar drugs?

0 of 20 similar drugs in Muscle Spasticity were approved

Approved (0) Terminated (0) Active (20)
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
🔄EperisoneEisaiPhase 3
🔄Botulinum Toxin Type AAbbViePhase 3
🔄BOTOX + PlaceboAbbViePhase 3
🔄BOTOX + PlaceboAbbViePhase 3
🔄BOTOX + Placebo for BOTOXAbbViePhase 3
🔄BOTOX + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (14)

NCT IDPhaseStatus
NCT03569098Phase 2Completed
NCT03598777Phase 2Terminated
NCT02493946Phase 3Completed
NCT02353871Phase 3Completed
NCT02321436ApprovedCompleted
NCT01753310Phase 3Completed
NCT01249417Phase 3Completed
NCT01357980Phase 2Completed
NCT01249404Phase 3Completed
NCT00578097Phase 2Terminated
NCT00257660Phase 3Completed
NCT00447876Phase 2/3Completed
NCT00216411ApprovedCompleted
NCT00234546ApprovedCompleted

Competing Products

20 competing products in Muscle Spasticity

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
EperisoneEisaiPhase 3
40
LY2495655 + PlaceboEli LillyPhase 2
35
HRS-9190Jiangsu Hengrui MedicinePhase 1
29
HRS-9190 for InjectionJiangsu Hengrui MedicinePhase 1
29
Botulinum Toxin Type AAbbViePhase 3
40
BOTOX + PlaceboAbbViePhase 3
40
BOTOX + PlaceboAbbViePhase 3
40
BOTOX + Placebo for BOTOXAbbViePhase 3
40
BOTOX + PlaceboAbbViePhase 3
40
Durvalumab + Tremelimumab + Enfortumab VedotinAstraZenecaPhase 3
44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Durvalumab + OleclumabAstraZenecaPhase 1
29
AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + SelumetinibAstraZenecaPhase 1
33
Durvalumab + Cisplatin + GemcitabineAstraZenecaPhase 3
44
Durvalumab + BCGAstraZenecaPhase 3
44
Durvalumab + MonalizumabAstraZenecaPhase 2
42